Abstract
Gong et al present two NCI-MATCH tumor-agnostic trials evaluating erdafitinib for FGFR-altered cancers, marking steppingstones in precision oncology.
MeSH terms
-
Humans
-
Mutation*
-
Neoplasms* / drug therapy
-
Neoplasms* / genetics
-
Precision Medicine
-
Pyrazoles / therapeutic use
-
Quinoxalines*
-
Receptors, Fibroblast Growth Factor / genetics
Substances
-
Receptors, Fibroblast Growth Factor
-
erdafitinib
-
Pyrazoles
-
Quinoxalines